Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide
Authors:
- Riley M. RandolphRRRiley M. Randolph
- Tyler C. DunlapTDTyler C. Dunlap
- Stephany Gonzalez TineoSTStephany Gonzalez Tineo
- Ryan M. KemperRKRyan M. Kemper
- Jing ZhuJZJing Zhu
- Kieran CollinsKCKieran Collins
- Yu Fei WangYWYu Fei Wang
- Pu OuyangPOPu Ouyang
- Nichole Korpi‐SteinerNKNichole Korpi‐Steiner
- Eric WeimerEWEric Weimer
- Morgan E. BizzellMBMorgan E. Bizzell
- Jonathan R. PtachcinskiJPJonathan R. Ptachcinski
- 29 September 2026
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (10) , e70305
Abstract
Allogeneic hematopoietic cell transplant (allo‐HCT) is potentially curative for many hematologic diseases but complicated by acute graft‐versus‐host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post‐transplant cyclophosphamide (PTCy). This single‐center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo‐HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo‐HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady‐state concentrations (C trough, ss ) using the current institutional weight‐based dosing strategy and the proposed model‐informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic C trough, ss (trough, ss values from 95 allo‐HCT recipients who received PTCy were included. The previous model did not successfully predict tacrolimus C trough, ss values among PTCy patients, but highlighted similarities between clearance in PTCy and standard aGVHD prophylaxis patients who received reduced‐intensity conditioning. Dosing simulations suggested a decreased proportion of PTCy patients would experience subtherapeutic tacrolimus C trough, ss with MIPD (3%) compared to conventional weight‐based dosing (23%).Keywords
Funding Information
- National Cancer Institute (5‐K12CA120780‐17)
This publication has 30 references indexed in Scilit:
- Electronic Patient File‐Embedded Model‐Informed Precision Dosing Compared with Physician Dosing of Tacrolimus in Kidney TransplantationClinical Pharmacology & Therapeutics, 2025
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRTransplantation and Cellular Therapy, 2025
- Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTRTransplantation and Cellular Therapy, 2025
- Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryTransplantation and Cellular Therapy, 2024
- Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patientPractical Laboratory Medicine, 2023
- Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2023
- Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)Genetics in Medicine, 2017
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2015
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- Racial disparities in hematopoietic cell transplantation in the United StatesBone Marrow Transplantation, 2011